Groundbreaking studies presented at Prostate Cancer Research Program's IMPaCT conference

Today, the nation's most prestigious minds in prostate cancer research unveiled the findings of their groundbreaking studies at the Prostate Cancer Research Program's (PCRP's) Innovative Minds in Prostate Cancer Today (IMPaCT) conference in Orlando, Florida. 

Leading prostate cancer clinicians, researchers, and consumer advocates (prostate cancer survivors) formed a unified front against the ravages of prostate cancer through their studies and stories at one of the largest prostate cancer research conferences in the U.S.  These findings are key developments in translating laboratory research into new and more effective treatments for men and their families affected by prostate cancer.

Featured press conference presenters include:

  • Dr. Lionel L. Banez, Assistant Professor of Urology in the Division of Urologic Surgery, Department of Surgery at Duke University Medical Center, and Director of the Duke Prostate Center Outcomes Database.
  • Mr. Joel Nowak, Prostate Cancer Consumer Advocate, Malecare.
  • Dr. Folakemi Odedina, Professor of Pharmaceutical Outcomes and Policy, and Director of Community Outreach and Minority Affairs at the University of Florida.
  • Dr. Brian Olson, Fellow at the University of Wisconsin, Madison, whose research includes tumor immunology with a focus on vaccine development.
  • Dr. Howard I. Scher, Chief of the Genitourinary Oncology Service and Professor of Medicine, Memorial Sloan-Kettering Cancer Center.
Source:

Department of Defense Prostate Cancer Research Program

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients